Pediatric Neuro-oncology
Research activity centers on pediatric low-grade glioma, with attention to tumors carrying activating RAF and BRAF alterations. The clinical focus includes children and adolescents with newly diagnosed, relapsed, or progressive disease requiring systemic therapy.
- Low-grade glioma
- RAF-altered brain tumors
- BRAF-mutant glioma
These studies reflect a strong interest in targeted treatment options for pediatric central nervous system tumors.
Targeted Therapy for MAPK-Pathway Alterations
The sponsor is involved in clinical research for tumors driven by activating RAF fusion and other MAPK pathway alterations. This includes disease settings where molecular profiling guides treatment selection in pediatric oncology.
- RAF fusion-positive tumors
- Activating RAF alterations
- Molecularly defined pediatric cancers
The therapeutic emphasis is on cancers with identifiable signaling abnormalities that can be matched to targeted treatment approaches.
Relapsed and Progressive Disease
Clinical studies also address relapsed and progressive pediatric tumors, including low-grade glioma and advanced solid tumors. These programs include patients whose disease has returned or continued to worsen after prior management.
- Relapsed glioma
- Progressive pediatric cancer
- Advanced solid tumors
This area extends the sponsor’s interest beyond initial treatment into harder-to-manage disease states in children and young adults.
Pediatric Solid Tumors
Beyond brain tumors, the sponsor’s portfolio includes advanced solid tumors in pediatric patients with activating RAF fusion changes. The work spans rare cancer populations where targeted options remain limited.
- Pediatric solid tumors
- RAF fusion-driven cancer
- Rare childhood malignancies
This broadens the therapeutic scope to include non-CNS malignancies with shared molecular features.
